Research overview
Thymalin: what the research shows
What is thymalin?
Thymalin is a thymus-derived peptide preparation. Its developers described isolating natural thymic peptides from calf thymus by mild acid extraction and introducing a preparation of these peptides, named Thymalin, into practice. They also reported isolating one immunomodulatory component, the dipeptide Glu-Trp, by reversed-phase HPLC [1]. A 2023 paper from the same research network identified Lys-Glu (KE) and Glu-Trp (EW) dipeptides as active substances of thymalin [5].
Because thymalin is described as a complex rather than a single molecule, it has no single sequence, formula, or molecular weight to report. Some databases attach the name to unrelated thymic peptides. For example, PubChem lists "Thymalin" as a synonym on its record for nonathymulin, a nine-residue thymic peptide that is a different compound [7]. We do not use that record as an identity reference.
Thymalin is also different from thymosin alpha-1, a single defined 28-residue peptide. See our thymosin alpha-1 page for that compound.
| Type | Thymic polypeptide complex (not a single defined sequence) |
|---|---|
| Origin in the literature | Peptides isolated from calf thymus by mild acid extraction |
| Components described | Lys-Glu (KE) and Glu-Trp (EW) dipeptides, per its developers |
| PubChem | No verified record. The record listing "Thymalin" as a synonym (CID 3085284) is nonathymulin, a different peptide. |
Who has studied it
The thymalin literature is concentrated in one research group. Most indexed papers come from Vladimir Morozov, Vladimir Khavinson, and colleagues at institutions in St. Petersburg, Russia, including the St. Petersburg Institute of Bioregulation and Gerontology [1] [3] [4] [5]. Much of the older literature was published in Russian-language journals [2] [3].
A smaller number of studies come from other groups in the region, such as a rat tumor-model study from Rostov-on-Don [6]. Independent replication outside this research community is scarce. Readers should weigh the findings below with that concentration in mind.
Published research
T-cell differentiation in early work
The developers' 1997 review reported that both the natural preparation and synthetic dipeptides derived from it influenced T-cell differentiation, intracellular cyclic nucleotides, and interleukin-2 and interferon release by blood lymphocytes in their experiments [1].
Hematopoietic stem cell differentiation
In a 2020 in vitro study, the group exposed human hematopoietic stem cells to thymalin and reported lower expression of the markers CD44 and CD117 and higher expression of CD28, which the authors interpreted as stimulation of differentiation toward mature CD28-positive T cells [4].
Cytokine release in a cell model
A 2023 study combined molecular docking and bioinformatic analysis of the KE and EW dipeptides with an in vitro model of LPS-induced inflammation in human peripheral blood mononuclear cells from four donors. The authors reported that thymalin and both dipeptides reduced IL-1beta, IL-6, and TNF-alpha in that model [5].
Tumor model
A 2018 study in rats with transplanted sarcoma 45 reported tumor growth suppression and microstructural changes in the thymus under the conditions the authors tested [6].
State of the human evidence
The developers have published clinical reports, largely in Russian-language journals, including a long-term observational study in older adults [3]. These reports come from the same research community, and we found no independent, registered randomized trials of thymalin in the indexed literature. We do not summarize their results here.
Findings from cell and animal models should not be read as evidence of safety or benefit in people.
Regulatory status
- Not FDA approved. We found no FDA-approved drug containing thymalin in Drugs@FDA (checked October 12, 2026) [8].
- Compounding. Thymalin is not named on FDA's page of bulk drug substances that may present significant safety risks (content current as of April 22, 2026) [9], nor on FDA's list of bulk drug substances nominated under section 503A (updated May 14, 2026) [10].
Rejuvatide supplies thymalin strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.
Testing and quality
The current lot of Rejuvatide thymalin was tested by an independent laboratory for purity by HPLC with mass-spectrometric identification, and has a separate USP <85> endotoxin certificate for the same lot. Both certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.
Browse related compounds in immune and cellular research peptides.
Storage of lyophilized material
Thymalin ships as a lyophilized (freeze-dried) powder. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.